

## 2015 impact factor of Translational Cancer Research: 1.757

## **Editorial Office**

Translational Cancer Research, AME Publishing Company, Guangzhou 510220, China Correspondence to: Editorial Office. Translational Cancer Research, AME Publishing Company, Guangzhou 510220, China. Email: tcr@amepc.org.

Submitted Jun 14, 2016. Accepted for publication Jun 14, 2016. doi: 10.21037/tcr.2016.06.16

View this article at: http://dx.doi.org/10.21037/tcr.2016.06.16

It is great to announce that *Translational Cancer Research (TCR)* gains its 2015 impact factor: 1.757, as per the latest Journal Citation Report released by Thomson Reuters on June 14, 2016 (*Figure 1*). This is the first impact factor that TCR has obtained since its coverage by Science Citation Index Expanded (SCIE), service of Thomson Reuters from October 2015.

Translational Cancer Research (Transl Cancer Res, TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) was first launched in June 2012. It is an open-access, peer-reviewed journal published bimonthly both in print and online. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. Published and run by AME Publishing Company, the operation of TCR journal is driven by the leadership and passion of Editor-in-Chief, Prof. Eric Chuang (National Taiwan University); Co-Editor-in- Chief, Prof. Huan Giap (Scripps Proton Therapy Center). They devote their time and bring their decades of experience in scientific research and publications for managing this journal.

The announcement of the first impact factor is a new mark for *TCR*, but also beginning of a higher developing

stage. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors and reviewers for their significant contributions, and we look forward to continuous cooperation with all above mentioned and those who are interested in translational cancer research to bring more exciting contents to readers in the coming future.

## **Acknowledgments**

Funding: None.

## **Footnote**

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the noncommercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

InCites <sup>™</sup> Journal Citation Reports <sup>®</sup>									THOMSON REUTERS				
Journal Profile: Translational Cancer Research													
Year	Total cites	Journal impact factor	Impact factor without journal self cites	5-year impact factor	Immediacy index	Citable items	Cited half-life	Citing half-life	Eigenfactor score	Article influence score	% articles in citable items	Normalized Eigenfactor	avg Jif Percentile
2015	235	1.757	1.682	1.633	0.119	59	2.4	5.6	0.00106	0.505	16.95	0.12071	22.30000
Copyright © 2016 Thomson Reuters													1

Figure 1 Journal Profile: Translational Cancer Research, from Journal Citation Reports®, Thomson Reuters.

Cite this article as: Editorial Office. 2015 Impact Factor of *Translational Cancer Research*: 1.757. Transl Cancer Res 2016;5(S1):S151. doi: 10.21037/tcr.2016.06.16